EXTH-16. THE ORAL IRON-MIMETIC GALLIUM MALTOLATE SUPPRESSES TREATMENT-RESISTANT GLIOBLASTOMA – IN VIVO VALIDATION

Abstract BACKGROUND We previously reported on our in vitro and vivo studies using the metallocompound gallium maltolate (GaM) to target glioblastoma (GBM). demonstrated a profound cytotoxic effect vitrov vivo. Additionally, preliminary data suggested substantial inhibitory tumor growth, as well significant extension of disease-specific survival (OS). Here, we further validate effects GaM METHODS In irradiated adult GBM U87-MG cells were stereotactically implanted into right striatum male female athymic rats. Advanced MR imaging at 9.4T was carried out weekly starting two weeks after implantation. Daily oral (50 mg/kg) or vehicle provided confirmation. Longitudinal advanced MRI parameters processed for enhancing ROIs OsiriX 8.5.1 (lite) with Imaging Biometrics Software (Imaging LLC,). Statistical analyses included Kaplan-Meier plots, linear mixed model (LMM) comparisons, t-statistic slopes comparison (as indicator growth rate). RESULTS Median OS pilot cohort (5 control, 5 GaM) 28 51 days, respectively; 31 59 days replication (1 3 GaM); 37 48 (6 7 GaM). GaM-treated xenograft tumors grew significantly slower than control sex time dependent rates. No differences seen between cohorts both treatment groups all timepoints. Hence, subsequent performed pooled data. 30.5 groups, respectively (p < .001). A strong correlation (Χ2 = 6.238187; p .0125) suppression (LMM; .0001) evident. CONCLUSION have successfully validated